Yes, adenocarcinoma is a non-squamous cancer. In lung cancer specifically, the term “non-squamous” is a formal classification that separates adenocarcinoma and large cell carcinoma from squamous cell carcinoma, and this distinction directly affects which treatments you can receive.
The reason this matters so much is that several effective therapies are approved only for non-squamous non-small cell lung cancer (NSCLC) and are explicitly not indicated for squamous cell types. Understanding where adenocarcinoma falls in this system isn’t just academic; it shapes treatment decisions from diagnosis onward.
How Lung Cancer Is Classified
Lung cancer splits into two broad categories: small cell and non-small cell (NSCLC). About 80-85% of lung cancers are NSCLC, and these are further divided into three main types: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
From there, oncologists group NSCLC into two treatment-relevant buckets: squamous and non-squamous. Adenocarcinoma and large cell carcinoma fall into the non-squamous category. This grouping exists because squamous and non-squamous tumors behave differently, grow in different parts of the lung, carry different genetic mutations, and respond to different drugs.
What Makes Adenocarcinoma Different From Squamous
These two cancers originate from entirely different cell types. Adenocarcinoma develops from glandular cells, the kind that line organs and produce mucus or other secretions. Under a microscope, adenocarcinoma cells form ring-like structures with open centers, and many produce mucin, a thick gel-like protein that acts as a lubricant in healthy tissue.
Squamous cell carcinoma, by contrast, arises from flat, scale-like cells that normally serve as a protective lining in the airways. These tumors often show keratinization, producing the same tough protein found in skin and nails. Pathologists may see distinctive “keratin pearls” at the center of squamous tumors, a feature never present in adenocarcinoma.
The two types also tend to grow in different locations. Squamous cell carcinoma typically develops in the central airways of the lung, while adenocarcinoma more often appears in the outer (peripheral) regions. On imaging, adenocarcinoma is more likely to show up as ground-glass opacity, a hazy appearance on CT scans, which was present in nearly 39% of adenocarcinoma patients compared to 0% of squamous cell patients in one large retrospective study.
How Pathologists Tell Them Apart
When a biopsy sample is small, which is common with lung cancer, pathologists use protein markers to confirm the cancer type. The standard first-line approach is a two-marker panel. One marker, TTF-1, is typically positive in adenocarcinoma. The other, p63, lights up in squamous cell carcinoma. This combination correctly classifies the majority of tumors. In the small number of cases where results are unclear, a third marker called CK5/6 is added to reach a definitive answer.
Getting this classification right is not optional. It determines which therapies are safe and effective, so pathology reports for lung cancer almost always specify whether a tumor is squamous or non-squamous.
Why the Distinction Changes Treatment
The most practical reason the squamous vs. non-squamous label matters is drug eligibility. Pemetrexed, a widely used chemotherapy agent, is approved for non-squamous NSCLC in multiple treatment settings: as initial therapy combined with other drugs, as maintenance therapy, and as a single agent for recurrent disease. Its prescribing information explicitly states it is not indicated for squamous cell NSCLC.
This isn’t an arbitrary restriction. In clinical trials comparing treatment regimens, pemetrexed combined with cisplatin produced a median overall survival of 11.0 months in non-squamous patients, compared to 10.1 months for an alternative regimen. In squamous cell patients, the pattern reversed: pemetrexed plus cisplatin yielded only 9.4 months of median survival versus 10.8 months with the alternative. Pemetrexed was not just unhelpful in squamous tumors; patients did worse on it.
Genetic Mutations Favor Adenocarcinoma
One of the biggest advantages of having a non-squamous adenocarcinoma diagnosis, if there can be an advantage in cancer, is that adenocarcinoma carries a much higher chance of having a “targetable” genetic mutation. These are specific DNA changes in the tumor that can be attacked with precision drugs called targeted therapies, which often work better and cause fewer side effects than traditional chemotherapy.
About 25% of adenocarcinomas carry KRAS mutations, 14% have EGFR mutations, 8% have ALK rearrangements, and smaller percentages carry changes in BRAF, MET, ROS1, RET, and HER2. Each of these has approved targeted therapies or active clinical development. Squamous cell carcinoma, by contrast, carries these same mutations at rates below 5%. The most common genetic changes in squamous tumors involve tumor suppressor genes being turned off rather than oncogenes being turned on, which has proven much harder to target with drugs.
This is why molecular testing (also called biomarker testing) is standard practice after an adenocarcinoma diagnosis. Finding an EGFR mutation or ALK rearrangement can completely change a treatment plan, opening the door to oral medications that may control the cancer for months or years longer than chemotherapy alone.
Who Gets Each Type
Adenocarcinoma is the most common form of lung cancer overall, but it dominates even more among people who have never smoked. Between 60% and 80% of lung cancers in never-smokers are adenocarcinomas, compared to only about 24% of lung cancers in people who have smoked. Squamous cell carcinoma shows the opposite pattern: it accounts for 41% of lung cancers in smokers but only 10-15% in never-smokers.
This means adenocarcinoma is the type most likely to be diagnosed in someone with no traditional risk factors for lung cancer. It also tends to occur more frequently in women and in younger patients compared to squamous cell carcinoma.